Pulse Biosciences (PLSE) announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences Grants RSUs to Chief Technology Officer
- Pulse Biosciences Realigns Strategy Around nPulse AFib Platform
- Pulse to accelerate development of nPulse Cardiac Catheter Ablarton System
- Pulse Biosciences Launches Thyroid Cancer Feasibility Study
- Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn